Drug Trial Radar · NCT05032820
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 5, 2022
Primary completion
Aug 22, 2024
Study completion Feb 20, 2025
Sponsor
- Lead sponsor
- Medical College of WisconsinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program; Celgene a wholly owned subsidiary of BMS
- First posted
- Sep 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
Conditions
- Multiple Myeloma
Interventions
LenalidomideDrug
Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression
bb2121Biological
Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\^6 cells.
CyclophosphamideDrug
300 mg/m\^2/day for 3 consecutive days prior to the CAR T infusion
FludarabineDrug
30 mg/m\^2/day or 3 consecutive days prior to the CAR T infusion
leukapheresisProcedure
Placement of central line catheter and leukapheresis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of BCMA CAR-T Cell TherapyTime frame: 6 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Stanford Hospital and Clinics
Palo Alto, California
University of California, San Francisco
San Francisco, California
H. Lee Moffitt Cancer Center
Tampa, Florida
Loyola University Medical Center
Maywood, Illinois
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Roswell Park Cancer Center
Buffalo, New York
Mount Sinai Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Pennsylvania Hospital Center
Philadelphia, Pennsylvania
Baylor College and Medicine
Houston, Texas
University of Virginia
Charlottesville, Virginia
University of Wisconsin Hospitals and Clinics
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.